key: cord-0902242-vleod9j7
authors: Almamlouk, Raghed; Kashour, Tarek; Obeidat, Sawsan; Bois, Melanie C.; Maleszewski, Joseph J.; Omrani, Osama A.; Tleyjeh, Rana; Berbari, Elie; Chakhachiro, Zaher; Zein-Sabatto, Bassel; Gerberi, Dana; Tleyjeh, Imad M.
title: COVID-19-associated cardiac pathology at post-mortem evaluation: A Collaborative systematic Review
date: 2022-03-23
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2022.03.021
sha: 4315d31a45a53ebbe885f71b654a66b3a1d14bf4
doc_id: 902242
cord_uid: vleod9j7

BACKGROUND: Many post-mortem studies addressing the cardiovascular effects of COVID-19 provided valuable information but were limited by their small sample size. OBJECTIVE: The aim of this systematic review is to better understand the various aspects of the cardiovascular complications of COVID-19 by pooling data from a large number of autopsy studies. DATA SOURCES: We searched online databases Ovid EBM Reviews, Ovid Embase, Ovid Medline, Scopus and Web of Science for the concepts of autopsy or histopathology combined with COVID-19 published between database inception to February 2021. We also searched for unpublished manuscripts using the medRxiv services operated by Cold Spring Harbor Laboratory. STUDY ELIGIBILITY CRITERIA, PARTICIPANTS, INTERVENTIONS: Articles were considered eligible for inclusion if they reported human post-mortem cardiovascular findings among individuals with confirmed SARS-CoV-2 infection. ASSESSMENT OF RISK OF BIAS: Studies were individually assessed for risk of selection bias, detection bias and reporting bias. METHODS OF DATA SYNTHESIS: Median prevalence of different autopsy findings with associated interquartile ranges. RESULTS: This review cohort contained 50 studies including 548 hearts. The median age of the deceased was 69 years. The most prevalent acute cardiovascular findings were myocardial necrosis (median=100.0%, IQR 20-100%, number of studies=9, number of patients=64) and myocardial edema (median=55.5%, IQR 19.5-92.5%, number of studies=4, number of patients=46). Median reported prevalence’s of extensive, focal active and multifocal myocarditis were all 0.0%. The most prevalent chronic changes were myocyte hypertrophy (median=69.0%, IQR 46.8-92.1%) and fibrosis (median=35.0%, IQR 35.0-90.5%). SARS-CoV-2 was detected in the myocardium with median prevalence of 60.8% (IQR 40.4-95.6%). CONCLUSION: Our systematic review confirmed the high prevalence of acute and chronic cardiac pathologies in COVID-19, SARS-CoV-2 cardiac tropism, and the low prevalence of myocarditis in COVID-19 disease.

Cardiac abnormalities were found on gross pathology or histology in almost all cases. 1

Heart weights were available for 276 hearts (51%), with the median weight being 465 gm (range 2 238-1070 gm). 3 Heart 4 5 Nineteen studies (17) (18) (19) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) with 217 cases explored presence and localization of 6 SARS-CoV-2 in the heart using different modalities including reverse transcription polymerase 7 chain reaction (RT-PCR), immunohistochemistry, in situ hybridization and electron microscopy. 8

Ten studies (18, 19, (26) (27) (28) 30, 32, 33, 35, 37) with total of 116 cases detected SARS-CoV-2 in 9 cardiac tissues in 70 cases with a median of 60.8% (IQR 40.4-95.6%) ( Figure 3 ). 10

Active replication of SARS-CoV-2 virus within the heart was determined using the 11 RNAscope in situ hybridization technique looking for the presence of the negative strand of the 12 SARS-CoV-2 viral ribonucleic acid (RNA) or through identification of subgenomic RNA, both 13 of which indicate active viral replication. Four investigators employed these techniques in 55 14 cases (18, 27, 28, 33) and verified presence of active SARS-CoV-2 viral replication in 15 (27%) 15

Localization of SARS-CoV-2 virus within different cardiac cell compartments was 17 studied by nine investigators (23, 25, 26, 30, 33, 34, (36) (37) (38) in 56 hearts from total of 95 cases using 18 electron microscopy or immunohistochemistry. The presence of SARS-CoV-2 within the 19 cardiomyocytes was reported in 11 hearts by four investigators (30, 33, 34, 36) . SARS-CoV-2 was 20 also detected in cardiac vascular endothelial cells in seven hearts and in cardiac fibroblasts in one 21 heart (26,34). On the other hand, other investigators (23,25,26,37,38) could not detect SARS-22

CoV-2 within any cell type in the heart. 23

J o u r n a l P r e -p r o o f

The majority of studies did not specify what definition of myocarditis that was used. 1 However, from the description of histopathological findings, it is inferred that Dallas criteria was 2 used by most. Several investigators used immunohistochemical studies with different antibodies 3 to identify subtypes of cellular infiltrates, but most did not use immunohistochemical criteria to 4 diagnose myocarditis. In total, 36 cases had myocarditis, and 16 had inflammatory infiltrates but 5 no myocyte damage. (Figure 3 ) 6

Few cases reported extensive myocarditis, ranging from 0.0% to 19.3% with a median of 7 0.0% across 10 studies (20, 23, 26, 28, 32, 37, (39) (40) (41) (42) with total of 175 cases ( Figure 3 ). Grosse et 8 al., the only consecutive study to report prevalence for this finding, did not find any cases of 9 extensive myocarditis across 14 cases. Focal active myocarditis was reported by 13 studies 10 (20, 21, 23, 25, 26, 28, 32, [37] [38] [39] [40] 42, 43) , ranging from 0.0% to 55.5%. Nine studies 11 (19, 20, 26, 28, 32, 37, 39, 42, 44) acute myocardial infarction had the lowest reported median prevalence in this category 2 (median=11.8%, IQR 7.9-13.8%) ( Figure 3 ). 3

Acute epi-pericarditis was reported with a median prevalence of 15.5% (IQR 11.9-4 19.2%) across six studies (28, 30, 33, 38, 39, 41) in 29/110 cases whilst small vessel vasculitis had a 5 median reported prevalence of 28.6% (IQR 16.0-32.5%) across three studies (38,41,43) in 12/86 6 cases ( Figure 3) . 7

Other less frequently reported findings include single-cell ischemia in 1/7 patients (35), 8 myocyte ischemic degeneration with pyknosis in one case report (50), and contraction bands in 9 1/3 cases (51). 10

Hypertrophy was the most common pathological finding with a median of 69.0% ( and was determined to be transthyretin (ATTR) in 13 cases and amyloid P in one case, with the 23 J o u r n a l P r e -p r o o f age of these patients ranging between 71-96 years (20,23, 28, 31, 35, 45) . Other less reported 1 pathologies were chronic pericarditis reported by three studies in 17/47 cases (28, 33, 43) , and 2 ischemic heart disease in 1/3 cases in one study (50). General autopsy findings and clinical correlation 8

This systematic review of pathology-derived cardiac changes in COVID-19 included 50 9 studies with over 500 cases and was the effort of an international collaboration. 10

The most prevalent chronic changes were myocardial hypertrophy, underlying CAD and 11 fibrosis (with medians of 69.0%, 46.2%, and 42.9%, respectively). The high prevalence of 12 chronic cardiac pathologies among patients who died due to COVID-19 supports findings from 13 previously published epidemiological studies (1-3). 14 Interestingly, another underlying cardiac disease, amyloidosis, was reported in a median 15 of 13.6% of COVID-19, with age ranging between 71-96 years. The overall prevalence of 16 cardiac amyloidosis in an unselected, sequential autopsy population has been reported to be 17 approximately 4% (23,52). Conversely, a Finnish autopsy study of individuals above 85 years of 18 age detected cardiac amyloidosis in 25% of cases (53). While cardiac amyloidosis almost 19 certainly increases in prevalence with patient age, it is also likely underdiagnosed, particularly 20 among those patients with heart failure with preserved ejection fraction (HFpEF) (54-56). 21

Nevertheless, the relatively high proportion of cardiac amyloidosis among COVID-19 decedents 22 when compared to unselected autopsy rates suggests that this condition may render patients 23 vulnerable to adverse outcomes from SARS-CoV-2 infection. This is further supported by the 24 average age of patients with cardiac amyloidosis who died of COVID-19. Possible mechanisms 1 for this complication have been proposed, however, it is likely that decreased cardiac reserve 2 innate to underlying cardiovascular disease, including amyloidosis, plays a significant role (57). 3

The prevalence of acute thrombo-embolic pathologies in descending frequency included 4 micro-vessel thrombi (36.2%), pulmonary embolism (22.2%), cardiac large vessel thrombosis 5 (14.3%) and acute myocardial infarction (11.8%). The increased cardiac and pulmonary vascular 6 thrombi correlate strongly with the clinical evidence of increased thromboembolic phenomena in 7 COVID-19. Moreover, these thrombotic changes, along with the observed high prevalence of 8 acute cardiac injuries such as necrosis, edema, and epicarditis-pericarditis, are concordant with 9 the clinically documented ventricular dysfunction (6) and serologic markers of cardiac injury 10 such as increased troponins (7-10). In fact, microvascular thrombosis has been cited as the 11 causative agent of cardiac injury in most COVID-19 decedents (58). This finding dovetails with 12 the lower prevalence of large vessel cardiac thrombosis and is consistent with the coronary 13 angiographic findings in COVID-19 patients, wherein a culprit lesion was not identified in over 14 40% of patients with suspected acute myocardial infarction (14) . 15

The SARS-CoV-2 virus gains entry to the host cells through the binding of its spike (S) 18 protein to the angiotensin-converting enzyme 2 (ACE2) with the help of the host transmembrane 19 protease TMPRSS-2 (59). Both proteins have been shown to be expressed in the heart (23,60-20 62). The predecessor of the SARS-CoV-2 virus, SARS-CoV (and its associated syndrome 21 SARS), also uses the ACE2 protein for cell entry and had been shown to infect the heart and 22

induce inflammatory changes based on data from the first decade of the 21 st century (62). These 23 findings, along with the clinical observations of acute cardiac injury among COVID-19 patients, 1

prompted several investigators to address three important questions; namely, (1) is the SARS-2 CoV-2 virus present in the hearts COVID-19 decedents, (2) if so, which cell type(s) does it 3 infect, and (3) can it replicate in the heart tissues? 4

Twenty studies explored the presence of SARS-CoV-2 virus within the heart, the 5 majority of which targeted identification of SARS-CoV-2 ribonucleic acid (RNA) in the heart 6 tissues using RT-PCR or in situ hybridization. Other employed techniques include 7 immunohistochemistry aiming at identifying SARS-CoV-2 proteins such as spike (S) protein or 8 nucleocapsid protein, as well as electron microscopy. These investigators identified the presence 9 of SARS-CoV-2 in almost 60% of examined hearts. Additionally, a few investigators identified 10 SARS-CoV-2 replication within the heart tissues in several cases (18, 27, 28, 33) . Furthermore, 11 studies investigated cell type localization of SARS-CoV-2 within the heart and provided 12 evidence of presence of SARS-CoV-2 viral particles within the cardiomyocytes (30, 33, 34, 36) . In this review, we subdivided the reported cardiac inflammatory processes in COVID-19 5 patients into four categories based on the degree of myocardial involvement and the presence of 6 associated myocyte damage. Overall, the prevalence of each category was low, with vast 7 differences between individual studies that cannot be explained solely by methodological 8 differences of the studies and likely indicate significant selection and reporting bias. 9

The median reported prevalence of extensive myocarditis, multifocal active myocarditis 10 and focal active myocarditis were all 0.0%, while the median prevalence of inflammatory 11 infiltrate without myocyte damage was 0.6%. There was no funding source for this study. 5

None. 7

Access to data 8

All extracted data are available in the manuscript and supplemental documents. 9

Contribution 10 IMT designed the study. IMT, RA, SO, and MCB coordinated the study. DG designed and ran 11 the literature search. RA, SO, OAO, RT, ZC, BZS, EB and TK acquired data, screened records, 12 and extracted data. IMT and OAO did formal analyses. TK wrote the report with input from 13 MCB and JJM. All authors provided critical conceptual input, analysed, and interpreted data, and 14 critically revised the report. For more information, visit www.prisma-statement.org.

Records identified through database searching (n = 4736)

Additional records identified through other sources (n = 24)

Records after duplicates removed (n = 4760) 

Association of Use 2 of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With 3

Testing Positive for Coronavirus Disease 2019 (COVID-19)

System Inhibitors and Risk of Covid-19

System Blockers and the Risk of Covid-19

The Novel Coronavirus Pneumonia Emergency Response Epidemiology T. The 10 Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-11 19) -China

Long-term cardiovascular outcomes of COVID-19. 13 Nature Medicine

Global 15 evaluation of echocardiography in patients with COVID-19

Clinical Characteristics of 138 18 Hospitalized Patients With

Cardiovascular Implications of Fatal 21 Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Clinical course and risk factors for 24 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Association of Cardiac Injury With 27 Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Cardiac injury is 30 associated with mortality and critically ill pneumonia in COVID-19: A meta-analysis

Cardiovascular 33 manifestations and treatment considerations in COVID-19

The Heart in COVID-19: Primary Target or Secondary Bystander? JACC: Basic 35 to Translational Science

ST-Elevation Myocardial Infarction in Patients With COVID-19: Clinical and Angiographic 38 Outcomes

SARS-CoV-2: a potential novel etiology of fulminant 40 myocarditis. Herz. 452020. p. 230-2. 41 16

Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients. Critical 2 Care

Evidence of SARS-CoV-2 Transcriptional Activity in Cardiomyocytes of COVID-19 Patients 5 without Clinical Signs of Cardiac Involvement

SARS-CoV-2 in cardiac tissue of a child with 8 COVID-19-related multisystem inflammatory syndrome. The Lancet Child & Adolescent 9 Health

Histopathological findings in fatal COVID-19 severe acute respiratory 12 syndrome: preliminary experience from a series of 10 Spanish patients

-2 fulminant myocarditis: an autopsy and histopathological case study

Pathology 18 and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease

Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in 22 COVID-19: A case series

Postmortem 24 Examination of Patients With COVID-19

Pathological Findings of Postmortem Biopsies From Lung, Heart, and Liver of 7 Deceased 27 COVID-19 Patients

Negative Myopericarditis in Human Coronavirus Infection. Circulation: Heart Failure

Postmortem Examinations in COVID-19 Patients

Postmortem 34 Findings in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of Cases With 35 and Without Comorbidities

Pulmonary 40 Arterial Thrombosis in COVID-19 With Fatal Outcome : Results From a Prospective

Clinicopathologic Case Series

Segment-Elevation Myocardial Infarction in COVID-19

The emerging 45 spectrum of cardiopulmonary pathology of the coronavirus disease

Eosinophilic Myocarditis in a Healthy 17-Year-Old Male with Severe Acute Respiratory 4 Syndrome Coronavirus 2 (SARS-CoV-2c)

Mortem Diagnosis and Autopsy Findings in SARS-CoV-2 Infection: Forensic Case Series

Histopathological features 9 of multiorgan percutaneous tissue core biopsy in patients with COVID-19

COVID-19 autopsy in people who died in community settings: the 12 first series

COVID-14 19-Associated Nonocclusive Fibrin Microthrombi in the Heart

Wild-type transthyretin amyloidosis as a cause of heart failure with 18 preserved ejection fraction

Pilot study for 20 left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved 21 ejection fraction: the high prevalence of amyloid cardiomyopathy. The International Journal of 22 Cardiovascular Imaging

Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. 25 JACC Heart Fail

ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable

Microthrombi as a Major Cause of Cardiac Injury in COVID-19

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically 34 Proven Protease Inhibitor

Single-cell analysis of SARS-CoV-36 2 receptor ACE2 and spike protein priming expression of proteases in the human heart

SARS-42 coronavirus modulation of myocardial ACE2 expression and inflammation in patients with 43 SARS

SARS-CoV-2 infection of human iPSC-derived cardiac cells predicts novel cytopathic features

Multisystemic Cellular Tropism of SARS-CoV-2 in Autopsies of COVID-19 Patients

COVID-19-related fatal myocarditis in a 42-year-old 9 female patient

Factors 11 associated with myocardial SARS-CoV-2 infection, myocarditis, and cardiac inflammation in 12 patients with COVID-19

A Clinical Trial of Immunosuppressive Therapy for Myocarditis

Interobserver variability in the pathologic interpretation of endomyocardial biopsy results

Evaluation of Postmortem Endomyocardial 20 Biopsy Specimens From 38 Patients With Lymphocytic Myocarditis: Implications for Role of 21 Sampling Error

Halushka MK, Vander Heide RS. Myocarditis is rare in COVID-19 autopsies: 29 cardiovascular findings across 277 postmortem examinations. Cardiovascular pathology : the 30 official journal of the Society for Cardiovascular Pathology

Placebo-Controlled Study for Immunosuppressive Treatment of 33 Inflammatory Dilated Cardiomyopathy

Cardiac Magnetic 35 Resonance Imaging in Coronavirus Disease 2019 (COVID-19): A Systematic Review of Cardiac 36

Magnetic Resonance Imaging Findings in 199 Patients

Guidelines for 38 autopsy investigation of sudden cardiac death: 2017 update from the Association for European 39 Cardiovascular Pathology

Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a 42 position statement of the European Society of Cardiology Working Group on Myocardial and 43 Pericardial Diseases

J o u r n a l P r e -p r o o f